Niraparib for Colorectal Cancer
This trial is testing niraparib and panitumumab to see if they're effective at treating colorectal cancer.
- Metastatic Microsatellite Stable Colorectal Cancer
- Colorectal Carcinoma
- Microsatellite Stability
- RAS Wild Type
- Colorectal Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is there an ongoing recruitment effort for this clinical experiment?
"As evidenced on clinicaltrials.gov, this study is currently recruiting volunteers and was first made available to the public in October of 2019 with its most recent update occurring November 1st 2022."
How many participants have enrolled in this clinical investigation?
"Affirmative. As indicated by clinicaltrials.gov, this medical investigation is currently seeking volunteers; first posted on October 15th 2019 and last updated November 1st 2022. 40 participants have to be sourced from 3 locations for the trial's completion."
Are there previous investigations concerning Niraparib?
"As of now, 131 clinical trials are in progress for Niraparib. 16 of these studies are currently at Phase 3 and there is a total of 3374 sites hosting the research. The bulk of these investigations take place within Washington D.C., however other locations across the United States also offer access to these resources."
Has the Drug and Food Administration sanctioned the use of Niraparib?
"The safety of niraparib was rated a 2 on our scale, as although there is some evidence confirming its security, no data exists to display the efficacy."
Is this an unprecedented medical experiment?
"Amgen first initiated the research of niraparib in 2011 and, following a successful Phase 1 trial involving 75 patients, granted it approval for Phase 2 testing. Currently there are 131 active trials occurring across 561 cities within 50 countries."